Hospital
Hca Health Services of Tennessee, INC.
Hca Health Services of Tennessee, INC. was paid $27.54M by Medicaid between Jan 2018 and Dec 2024, across 93 billing codes. Its largest line is 99283, emergency room visit (moderate) — 54% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF TENNESSEE, INC.
NASHVILLE, TN 37211
NASHVILLE, TN 37211
33aNPI1720032345assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.54M
24GClaims371,487
24DCodes billed93
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#8 of 71
Median peer was paid$6.96M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,212 | $4.53M | |
| 2019 | 57,323 | $4.00M | |
| 2020 | 42,063 | $2.71M | |
| 2021 | 45,844 | $3.42M | |
| 2022 | 58,728 | $4.41M | |
| 2023 | 66,327 | $4.81M | |
| 2024incomplete | 38,990 | $3.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 54% | 60,372 | 55,289 | $14.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 35% | 38,825 | 33,636 | $9.63M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.5% | 22,896 | 19,768 | $1.24M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 7,196 | 6,870 | $1.16M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 8,497 | 8,038 | $176K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 242 | 194 | $92K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,839 | 4,222 | $81K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,553 | 589 | $67K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 190 | 156 | $50K |
| 97802 | <1% | 581 | 545 | $46K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 784 | 338 | $42K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,212 | 1,139 | $34K |
81 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 632 | $33K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 167 | $26K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 36 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,190 | $10K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 16 | $8K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,255 | $8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 320 | $8K |
| 80053 | Comprehensive metabolic panel | <1% | 31,944 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 579 | $7K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12,499 | $7K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 521 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 22 | $5K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 41 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,547 | $4K |
| 85027 | <1% | 40,574 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,967 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,141 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,116 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,320 | $2K |
| 97162 | <1% | 15 | $1K | |
| 81025 | <1% | 13,459 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 90 | $927.42 |
| 83690 | <1% | 8,710 | $688.01 | |
| 81001 | <1% | 17,010 | $593.58 | |
| 87430 | <1% | 1,748 | $518.26 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,233 | $463.53 |
| 87081 | <1% | 540 | $423.90 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 581 | $371.25 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,776 | $298.73 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,874 | $291.61 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,106 | $236.21 |
| 84484 | <1% | 7,452 | $219.94 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,651 | $166.22 |
| 87631 | <1% | 153 | $141.07 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 928 | $120.52 |
| 74022 | <1% | 13 | $97.18 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 335 | $55.48 |
| 87503 | <1% | 1,390 | $49.99 | |
| 81003 | <1% | 5,800 | $44.55 | |
| 83735 | <1% | 2,717 | $42.44 | |
| 83880 | <1% | 138 | $37.07 | |
| 85610 | <1% | 1,521 | $24.10 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 23 | $22.56 |
| 87807 | <1% | 52 | $11.43 | |
| 87070 | <1% | 1,293 | $8.21 | |
| 80076 | <1% | 723 | $8.17 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 560 | $6.54 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $0.24 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 44 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 158 | $0.00 |
| 85378 | 0% | 147 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 51 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 178 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 29 | $0.00 |
| 84702 | 0% | 12 | $0.00 | |
| 82248 | 0% | 62 | $0.00 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 13 | $0.00 |
| 87186 | 0% | 16 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 18 | $0.00 |
| 80143 | 0% | 12 | $0.00 | |
| 87420 | 0% | 12 | $0.00 | |
| 87634 | 0% | 15 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 15 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
| 80179 | 0% | 12 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 105 | $0.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 174 | $0.00 |
| 82550 | 0% | 220 | $0.00 | |
| 84703 | 0% | 358 | $0.00 | |
| 85730 | 0% | 345 | $0.00 | |
| 82150 | 0% | 77 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 121 | $0.00 |
| A9270 | Non-covered item or service | 0% | 38 | $0.00 |
| 36000 | 0% | 63 | $0.00 | |
| 83605 | 0% | 17 | $0.00 | |
| 88304 | 0% | 12 | $0.00 | |
| 82077 | 0% | 40 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 67 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 34 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 14 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOFFMAN, ANDREA (CFO)